Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

This study has been completed.
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Information provided by:
Synta Pharmaceuticals Corp. Identifier:
First received: October 5, 2005
Last updated: December 3, 2008
Last verified: December 2008

STA-5326 is an oral experimental drug that has been shown to block the release of interleukin-12 from peripheral blood mononuclear cells. Given this activity on the immune system, STA-5326 mesylate is a potential treatment for various autoimmune diseases, such as Crohn's disease, that are mediated by the inappropriate expression of Th1 cytokines.

This study is evaluating the use of STA-5326 mesylate in patients with moderate to severe, active Crohn's disease. Study visits include a screening visit, 4 treatment period visits over 4 weeks and a follow-up visit that will occur 7 days following the end of treatment. Subjects may continue treatment for an additional 4 weeks of open label STA-5326 mesylate administration that includes an additional 2 treatment period visits. Subjects will undergo a colonoscopy with biopsy collection at baseline, at the end of the 4 week blinded phase and at the end of the 4 week open label phase.

Condition Intervention Phase
Crohn's Disease
Drug: STA-5326 mesylate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Official Title: A Randomized, Double-Blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease

Resource links provided by NLM:

Further study details as provided by Synta Pharmaceuticals Corp.:

Primary Outcome Measures:
  • To measure the changes from predose in peripheral blood and mucosal cytokines in subjects with active CD after administration of STA-5326 mesylate or placebo for 4 weeks

Secondary Outcome Measures:
  • To measure changes in other immunologic parameters.
  • To explore the level of cell-surface markers and specific gene expression patterns.
  • To measure changes in laboratory surrogate efficacy markers.
  • To measure the proportion of subjects in clinical remission at Day 29.
  • To measure the proportion of subjects with a clinical response at Day 29.
  • To measure the proportion of subjects with both clinical remission and clinical response at Day 29.
  • To confirm STA-5326 mesylate (and metabolite) levels in blood following oral administration to CD patients.
  • To measure the changes in endoscopic scores from Baseline to Day 29.
  • To measure the changes in the Inflammatory Bowel Disease Questionnaire overall score from Baseline to Day 29.

Estimated Enrollment: 12
Study Start Date: November 2005

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Is male or female aged 18 through 75 years.
  • Has Crohn's disease diagnosed definitively prior to Screening (based upon clinical, endoscopic, radiologic imaging, or histological assessments).
  • Has a CDAI score of 220 to 450, inclusive at Baseline.

Exclusion Criteria:

  • Has any clinically significant disease (eg, renal, hepatic, neurological, cardiovascular, pulmonary, endocrinologic, psychiatric, hematologic, urologic, or other acute or chronic illness) that in the opinion of the investigator would make the subject an unsuitable candidate for this study.
  • Is a woman who has a positive pregnancy test, who is breast-feeding, or who is sexually active without using birth control during the course of the study and Follow-up period.
  • Is a woman of childbearing potential or a man who does not agree to use 2 forms of contraception during the course of the study and Follow-up period.
  • Has clinically significant hematologic, hepatic or renal laboratory abnormalities.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00234741

United States, Maryland
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Synta Pharmaceuticals Corp.
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Principal Investigator: Peter Mannon, MD National Institute of Allergy and Infectious Diseases (NIAID)
  More Information Identifier: NCT00234741     History of Changes
Other Study ID Numbers: 5326-11
Study First Received: October 5, 2005
Last Updated: December 3, 2008

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases processed this record on May 24, 2017